GlassScriptPhysician profile
Daniel Mark Vinson
NPI 1245804996
$4,605.64
in general payments reported to CMS, 2019-2025
11 companies · $888 in 2025
The $888 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $487 · 2023: $2,710 · 2024: $521 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585 · Travel and Lodging: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.65 |
| Travel and Lodging | $1,534.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,277.38 | 2023-2025 | Envista Mx60 Iol, Stellaris Elite, Akreos Ao Iol |
| Abbvie INC. | $472.01 | 2023-2025 | Durysta, Xen Glaucoma Treatment System |
| Alcon Vision LLC | $391.92 | 2022-2024 | Clareon, Centurion |
| Mallinckrodt Hospital Products INC. | $390.36 | 2025 | Acthar |
| Horizon Therapeutics Plc | $347.49 | 2022 | |
| Polynovo North America LLC | $209.67 | 2024-2025 | Novosorb Btm |
| Sight Sciences, INC. | $140.30 | 2024 | Omni Surgical System |
| Rxsight INC | $111.54 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece |
| Amgen INC. | $103.65 | 2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $102.86 | 2025 | Purified Cortrophin Gel |
| Glaukos Corporation | $58.46 | 2025 | Photrexa Viscous and Photrexa, Idosetr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Vinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.